by Eric Christianson | Oct 11, 2026 | Uncategorized
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as empagliflozin (podcast) (Jardiance) and dapagliflozin (Farxiga), are commonly used to manage type 2 diabetes. These medications can also provide important cardiovascular and kidney benefits. However, increased...
by Eric Christianson | Mar 8, 2026 | Endocrine Medication and Disease State Clinical Pearls
Diabetes management can be quite complex as it is a progressive disease, and goals can change depending on a variety of patient factors. In general, the ADA suggests an A1C goal of <7%, but in some cases, less stringent goals like <8% may be appropriate. The...
by Eric Christianson | Jan 18, 2026 | Endocrine Case Studies
Prescribing cascades don’t usually start with “bad” medications. In fact, they often begin with some of our most effective therapies. Metformin, SGLT2 inhibitors, and GLP-1 receptor agonists all have strong outcome data in type 2 diabetes. But when adverse effects are...
by Eric Christianson | Jul 30, 2025 | Endocrine Medication and Disease State Clinical Pearls
Ertugliflozin was first approved in 2017 for the treatment of type 2 diabetes. This medication is an SGLT2 inhibitor that prevents the resorption of glucose back into systemic circulation. It has been shown to be effective in lowering A1c and managing diabetes. In...
by Eric Christianson | Jun 15, 2025 | Endocrine Case Studies
One of my biggest pet peeves is the use of sulfonylureas with insulin. Recall that sulfonylureas stimulate the release of insulin and in many patients with Type 2 diabetes we may not be getting much out of the sulfonylurea or in some cases, the extra boost in insulin...
